Literature DB >> 22772381

The prognostic value of MARCKS-like 1 in lymph node-negative breast cancer.

Kristin Jonsdottir1, Hui Zhang, Darshni Jhagroe, Ivar Skaland, Aida Slewa, Benny Björkblom, Eleanor T Coffey, Einar Gudlaugsson, Rune Smaaland, Emiel A M Janssen, Jan P A Baak.   

Abstract

There is a need for new biomarkers to more correctly identify node-negative breast cancer patients with a good or bad prognosis. Myristoylated alanine-rich C kinase substrate like-1 (MARCKSL1) is a membrane-bound protein that is associated with cell spreading, integrin activation and exocytosis. Three hundred and five operable T(1,2)N(0)M(0) lymph node-negative breast cancer patients (median follow-up time 121 months, range 10-178 months) were evaluated for MARCKSL1 expression by immunohistochemistry and quantitative real-time PCR. The results were compared with classical prognosticators (age, tumor diameter, grade, estrogen receptor, and proliferation), using single (Kaplan-Meier) and multivariate survival analysis (Cox model). Forty-seven patients (15 %) developed distant metastases. With single and multivariate analysis of all features, MARCKSL1 protein expression was the strongest prognosticator (P < 0.001, HR = 5.1, 95 % CI = 2.7-9.8). Patients with high MARCKSL1 expression (n = 23) showed a 44 % survival versus 88 % in patients with low expression at 15-year follow-up. mRNA expression of MARCKSL1 in formalin fixed paraffin-embedded tissue was also prognostic (P = 0.002, HR = 3.6, 95 % CI = 1.5-8.3). However, the prognostic effect of high and low was opposite from the protein expression, i.e., low expression (relative expression ≤ 0.0264, n = 76) showed a 79 % survival versus 92 % in those with high expression of MARCKSL1 mRNA. Multivariate analysis of all features with distant metastases free survival as the end-point showed that the combination of MARCKSL1 protein and phosphohistone H3 (PPH3) has the strongest independent prognostic value. Patients with high expression (≥13) of PPH3 and high MARCKSL1 protein had 45 % survival versus 78 % survival for patients with low MARCKSL1 protein expression and high expression (≥13) of PPH3. In conclusion, MARCKSL1 has strong prognostic value in lymph node-negative breast cancer patients, especially in those with high proliferation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22772381     DOI: 10.1007/s10549-012-2155-9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  12 in total

1.  c-Jun N-terminal kinase phosphorylation of MARCKSL1 determines actin stability and migration in neurons and in cancer cells.

Authors:  Benny Björkblom; Artur Padzik; Hasan Mohammad; Nina Westerlund; Emilia Komulainen; Patrik Hollos; Lotta Parviainen; Anastassios C Papageorgiou; Kristiina Iljin; Olli Kallioniemi; Markku Kallajoki; Michael J Courtney; Mats Mågård; Peter James; Eleanor T Coffey
Journal:  Mol Cell Biol       Date:  2012-07-02       Impact factor: 4.272

2.  OLC1 is overexpressed in breast cancer and its expression correlates with poor patient survival.

Authors:  Qiao-Hong Ou-Yang; Zhong-Xiang Duan; Zheng Jin; Ji-Xiao Lei
Journal:  Tumour Biol       Date:  2014-06-01

3.  METTL14-Mediated miR-30c-1-3p Maturation Represses the Progression of Lung Cancer via Regulation of MARCKSL1 Expression.

Authors:  Fei Li; Jing Zhao; Lei Wang; Yantong Chi; Xiaori Huang; Wei Liu
Journal:  Mol Biotechnol       Date:  2021-09-29       Impact factor: 2.695

4.  Role of Epithelial-Mesenchyme Transition in Chlamydia Pathogenesis.

Authors:  Joseph U Igietseme; Yusuf Omosun; Olga Stuchlik; Matthew S Reed; James Partin; Qing He; Kahaliah Joseph; Debra Ellerson; Brigid Bollweg; Zenas George; Francis O Eko; Claudiu Bandea; Hsi Liu; Genyan Yang; Wun-Ju Shieh; Jan Pohl; Kevin Karem; Carolyn M Black
Journal:  PLoS One       Date:  2015-12-17       Impact factor: 3.240

5.  Nuclear NHERF1 expression as a prognostic marker in breast cancer.

Authors:  A Paradiso; E Scarpi; A Malfettone; T Addati; F Giotta; G Simone; D Amadori; A Mangia
Journal:  Cell Death Dis       Date:  2013-11-07       Impact factor: 8.469

6.  Validation study of MARCKSL1 as a prognostic factor in lymph node-negative breast cancer patients.

Authors:  Nina Gran Egeland; Marie Austdal; Bianca van Diermen-Hidle; Emma Rewcastle; Einar G Gudlaugsson; Jan P A Baak; Ivar Skaland; Emiel A M Janssen; Kristin Jonsdottir
Journal:  PLoS One       Date:  2019-03-11       Impact factor: 3.240

7.  Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients.

Authors:  Gui-Qi Zhu; Yi Yang; Er-Bao Chen; Biao Wang; Kun Xiao; Shi-Ming Shi; Zheng-Jun Zhou; Shao-Lai Zhou; Zheng Wang; Ying-Hong Shi; Jia Fan; Jian Zhou; Tian-Shu Liu; Zhi Dai
Journal:  J Transl Med       Date:  2019-06-18       Impact factor: 5.531

8.  ELL targets c-Myc for proteasomal degradation and suppresses tumour growth.

Authors:  Yu Chen; Chi Zhou; Wei Ji; Zhichao Mei; Bo Hu; Wei Zhang; Dawei Zhang; Jing Wang; Xing Liu; Gang Ouyang; Jiangang Zhou; Wuhan Xiao
Journal:  Nat Commun       Date:  2016-03-24       Impact factor: 14.919

9.  The highly expressed 5'isomiR of hsa-miR-140-3p contributes to the tumor-suppressive effects of miR-140 by reducing breast cancer proliferation and migration.

Authors:  Omar Salem; Nese Erdem; Janine Jung; Ewald Münstermann; Angelika Wörner; Heike Wilhelm; Stefan Wiemann; Cindy Körner
Journal:  BMC Genomics       Date:  2016-08-08       Impact factor: 3.969

Review 10.  A Unique Family of Neuronal Signaling Proteins Implicated in Oncogenesis and Tumor Suppression.

Authors:  Markus Hartl; Rainer Schneider
Journal:  Front Oncol       Date:  2019-04-17       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.